文章：

CK5/6与GATA3表达在复发性尿路上皮癌中的预后意义

Prognostic Significance of CK5/6 and GATA3 Expression in Recurrent Urothelial Carcinoma

原文发布日期：9 October 2025

DOI: 10.3390/cancers17193267

类型: Article

开放获取: 是

英文摘要：

Background/Objectives: The study aimed to determine whether the expression of CK5/6 and GATA3 is altered in UCa recurrences and to evaluate disease-free survival (DFS) and overall survival (OS) according to CK5/6 and GATA3 expression. Methods: A retrospective study was performed in 77 patients with UCa. Surgery was performed in 35 patients. UCa recurrence was observed in 75% of patients. An immunohistochemical assessment of CK5/6 and GATA3 was performed in the primary and recurrent UCa groups. Results: CK5/6(+) in primary UCa was associated with a 73% probability of CK5/6(+) recurrence (p= 0.000005) and incidence at a younger age. CK5/6(−) in primary UCa was associated with an 84% probability of CK5/6(−) recurrence (p= 0.000005) and incidence at older age. A higher probability of UCa GATA3(+) recurrence was a significant independent factor associated with longer OS (p= 0.015). A greater probability of UCa CK5/6(+) recurrence was a significant independent factor associated with shorter OS (p= 0.044). Patients with CK5/6(+)-only UCa recurrences had significantly worse OS compared to UCa patients with at least one CK5/6(−) recurrence. Conclusions: 1. CK5/6 and GATA3 in UCa recurrences may differ from CK5/6 and GATA3 expression in primary UCa. Intensified oncological surveillance is suggested for patients with recurrent CK5/6(+) 2. Patients with at least one UCa CK5/6(−) recurrence have better prognosis compared to patients with only CK5/6(+) recurrences.

摘要翻译： 

背景/目的：本研究旨在探讨CK5/6与GATA3在尿路上皮癌（UCa）复发灶中的表达是否发生改变，并根据CK5/6与GATA3的表达情况评估患者的无病生存期（DFS）与总生存期（OS）。方法：对77例UCa患者进行回顾性研究，其中35例接受手术治疗，75%的患者出现UCa复发。对原发灶与复发灶组织分别进行CK5/6与GATA3的免疫组化检测。结果：原发灶CK5/6阳性与73%的复发灶CK5/6阳性率相关（p=0.000005），且发病年龄更轻；原发灶CK5/6阴性则与84%的复发灶CK5/6阴性率相关（p=0.000005），且发病年龄更大。复发灶GATA3阳性率更高是延长OS的显著独立因素（p=0.015），而复发灶CK5/6阳性率更高则是缩短OS的显著独立因素（p=0.044）。与至少出现过一次CK5/6阴性复发的患者相比，仅出现CK5/6阳性复发的患者OS显著更差。结论：1. UCa复发灶中CK5/6与GATA3的表达可能不同于原发灶，建议对CK5/6阳性复发患者加强肿瘤学监测；2. 与仅出现CK5/6阳性复发的患者相比，至少出现过一次CK5/6阴性复发的患者预后更佳。

原文链接：

Prognostic Significance of CK5/6 and GATA3 Expression in Recurrent Urothelial Carcinoma